No Data
Hong Kong stock movement | CSTONE PHARMA-B (02616) rises nearly 7% as the new anti-cancer drug has submitted clinical trial applications in Australia.
CSTONE PHARMA-B (02616) rose nearly 7%. As of the time of this report, it has increased by 6.96%, priced at 2.46 Hong Kong dollars, with a trading volume of 11.9243 million Hong Kong dollars.
CSTONE PHARMA-B (02616.HK) appoints He Ye as an independent non-executive Director.
On December 30, Gelonghui reported that Ms. He Ye has been appointed as an independent non-executive Director, effective from December 30, 2024.
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
CSTONE PHARMA-B (02616.HK) has submitted a clinical trial application in Australia for its key product CS2009 (PD-1/VEGF/CTLA-4 tri-specific antibody).
Gelonghui, December 23 │ CSTONE PHARMA-B (02616.HK) announced that the company has submitted a clinical trial application in Australia for its heavyweight product CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody), which is used to treat various solid tumors. CS2009 is a trispecific antibody with an innovative structural design that simultaneously targets PD-1, VEGFA, and CTLA-4. CS2009 has a balanced affinity for anti-PD-1 and anti-CTLA-4, enabling it to preferentially target and block double-positive tumor-infiltrating lymphocytes.
Express News | CStone Announces Submission of Clinical Trial Application in Australia for Cs2009, an Innovative Pd-1/Vegf/Ctla-4 Trispecific Antibody
CStone Pharmaceuticals Enrolls First Patient in Phase 1B Trial for Anti-Tumor Drug
CStone Pharmaceuticals (HKG:2616) Not Doing Enough For Some Investors As Its Shares Slump 34%
